Disease · MONDO_0001384

myopia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. myopia. Diseases, record MONDO_0001384. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001384

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: myopia
Open Targets ID: MONDO_0001384
Other names: Close sighted, Myopias, Near sighted, Near sightedness, Nearsightedness, Nearsightednesses
Highest stage of its drugs: Approval, for 2 of its 17 drugs, from EMA Human Drugs and PMDA

Source Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ATROPINE SULFATE	CHEMBL2146146	Small molecule	Approval	EMA Human Drugs and PMDA	17	15	15	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Approval	PMDA	1	0	0	Drugs and targets
ATROPINE	CHEMBL517712	Small molecule	Phase 3	ClinicalTrials.gov	42	41	40	Drugs and targets
VEHICLE	CHEMBL2108661		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TETRACAINE	CHEMBL698	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
7-METHYLXANTHINE	CHEMBL321248	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
CODA-001	CHEMBL4298053		Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPENTOLATE	CHEMBL1201338	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
MITOMYCIN	CHEMBL105	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
LUTEIN	CHEMBL173929	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CHRM3	Muscarinic acetylcholine receptor M3	4	Muscarinic acetylcholine receptor M3 antagonist	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
SCN10A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6332	Drugs and targets
SCN8A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6334	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials62

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03350620	CHAMP: Study of NVK-002 in Children With Myopia	Phase 3	670	2024-11-27	Myopia	ATROPINE	Its record names the disease	ClinicalTrials.gov
NCT03334253	Low-Dose Atropine for Treatment of Myopia	Phase 3	200	2023-05-11	Myopia	ATROPINE	Its record names the disease	ClinicalTrials.gov
NCT02528123	VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia	Not applicable	114	2024-04-23	Myopia, Refractive Errors	BENOXINATE, DEXAMETHASONE, OFLOXACIN, PROPARACAINE, TOBRAMYCIN	Its record names the disease	ClinicalTrials.gov
NCT03374306	Topical Application of Low-concentration (0.01%) Atropine on the Human Eye With Fast and Slow Myopia Progression Rate	Not applicable	71	2024-10-16	Myopia	ATROPINE	Its record names the disease	ClinicalTrials.gov
NCT03312257	Bifocal & Atropine in Myopia (BAM) Study	Not applicable	49	2022-12-09	Refractive Errors	ATROPINE	Its record names the disease	ClinicalTrials.gov
NCT07494799	Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear		3,890		Progressive Myopia, Pediatric Myopia, Orthokeratology-related Myopia Progression	ATROPINE	Its record names the disease	ClinicalTrials.gov
NCT03918915	The Safety and Efficacy of SYD-101 in Children With Myopia	Phase 3	852		Nearsightedness, Near Sightedness, Near-sightedness	ATROPINE SULFATE, VEHICLE	Its record names the disease	ClinicalTrials.gov
NCT06209320	A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops	Phase 3	777		Myopia	ATROPINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT04770610	Study of OT-101 in Treating Myopia	Phase 3	678		Myopia, Progressive	ATROPINE, ATROPINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT06708156	The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression	Phase 3	606		Myopia, Myopia Progression	ATROPINE SULFATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 62

See all 62 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Atropine Group vs Placebo Group: deaths from any cause	0 of 125	0 of 62	187	NCT03334253	Trial comparisons
Atropine Group vs Placebo Group: serious adverse events	2 of 125	0 of 62	187	NCT03334253	Trial comparisons
Atropine 0.01% vs Artifical Tear: deaths from any cause	0 of 34	0 of 27	61	NCT03374306	Trial comparisons
Atropine 0.01% vs Artifical Tear: serious adverse events	0 of 34	0 of 27	61	NCT03374306	Trial comparisons

Papers from its trials23

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37440213	RESULT	1	PubMed
37080623	RESULT	1	PubMed
20601657	RESULT	1	PubMed
42957683	DERIVED	1	PubMed
42276557	DERIVED	1	PubMed
41949794	DERIVED	1	PubMed
41870844	DERIVED	1	PubMed
41254600	DERIVED	1	PubMed
40705323	DERIVED	1	PubMed
39803986	DERIVED	1	PubMed

1 to 10 of 23

See all 23 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001384

GET https://conductscience.org/api/diseases/v1/MONDO_0001384/trials?page=2

API reference For AI assistants